ANDHealth today announced that Roche Australia – a world leader in innovation and research-focused healthcare – has joined ANDHealth’s cooperative digital health commercialisation initiative as a Corporate Member to support the development and growth of Australia’s local digital health ecosystem.

Australia’s decades-long policy of supporting innovation, significant investment into digital health infrastructure, and successful management of the COVID-19 pandemic has created an unprecedented opportunity to deliver a robust, sustainable digital health industry. The industry however is hampered by commercialisation challenges including access to capital, customers, and expertise. ANDHealth’s partnership with Roche will provide Australian digital health entrepreneurs and innovators with access to world-class skills and expertise to meet these challenges.

“The partnership with Roche is a key milestone in enabling us to achieve our vision of creating a world-leading, integrated ecosystem for the development, commercialisation and implementation of evidence-based digital health technologies in Australia,” says ANDHealth CEO, Bronwyn Le Grice.

“The relationship between our two organisations further strengthens the ANDHealth model of support for the growth and maturation of Australia’s digital health industry – growth that will deliver highly skilled jobs, create economic opportunity and deliver better health outcomes for all Australians,” she said.

Roche is a world leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is consistently ranked among the top investors in research and development worldwide, across all sectors, reflecting their commitment to innovation and science.  

Stefan Plattner, Futures Community lead, Roche Australia, says the partnership with ANDHealth supports the Group’s aim to deliver three to five times more patient benefits over the next decade, at 50 per cent less cost to society. “As a pioneer in healthcare we are committed to driving ground breaking scientific and technological advances that have the potential to transform the lives of patients worldwide. But we can’t accomplish this on our own. Only by partnering with the brightest minds from diverse backgrounds can we serve the needs of patients.”

“We look forward to working with Roche and other key industry leaders who are part of our Corporate Member Network in building a strong digital health industry in Australia that is the foundation of a truly modern healthcare system, providing care to those who need it, whenever they need it, wherever they are,” said Le Grice.

About ANDHealth

ANDHealth’s unique, non-profit, industry-led model supports Australian digital health companies to navigate the commercialisation pathway from ideation to institutional investment and international market entry through highly specific programs and expert support.

By forming a multi-sectoral, multidisciplinary membership and working collaboratively across Australia, we bring proven expertise to our innovators and investors. Roche joins a group of highly committed industry leaders who support ANDHealth’s vision, including Novartis Pharmaceuticals, RMIT University, Murdoch Children’s Research Institute, Planet Innovation, Potential(x), Curve, Healthxl and HPM Executive.

ANDHealth is Australia’s only organisation specialised in the acceleration of commercialisation in digital health technologies and has a proven track record of accelerating the global scale-up of high growth potential companies creating jobs, advanced manufacturing, clinical trials, and patient impact. ANDHealth is also Australia’s only female-founded and female-led health technology accelerator.

About Roche Australia

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is one of the world’s largest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also a world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Roche’s pharmaceutical division in Australia employs over 300 people who are dedicated to pioneering life-changing healthcare for every Australian via the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Australian patients have access to around 40 Roche medicines and Roche is a continued leader in oncology.